78 results on '"Calverley, Peter"'
Search Results
2. Machine Learning and Prediction of All-Cause Mortality in COPD
3. Continuous positive airway pressure versus standard care for the treatment of people with mild obstructive sleep apnoea (MERGE): a multicentre, randomised controlled trial
4. Impact of smoking status and concomitant medications on the effect of high-dose N-acetylcysteine on chronic obstructive pulmonary disease exacerbations: A post-hoc analysis of the PANTHEON study
5. Safety of tiotropium/olodaterol in chronic obstructive pulmonary disease: pooled analysis of three large, 52-week, randomized clinical trials
6. Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary Disease
7. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial
8. Demographic Characteristics and Clinical Outcomes in Patients from Latin America Versus the Rest of the World: A TIOSPIR® Post-Hoc Analysis
9. Demographic Characteristics and Clinical Outcomes in Patients from Latin America Versus the Rest of the World: A TIOSPIR® Post-Hoc Analysis
10. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials
11. Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial
12. 64 - Chronic obstructive pulmonary disease
13. Determinants of exercise-induced oxygen desaturation including pulmonary emphysema in COPD: Results from the ECLIPSE study
14. Sarcopenic Obesity, Functional Outcomes, and Systemic Inflammation in Patients With Chronic Obstructive Pulmonary Disease
15. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial
16. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial
17. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial
18. Stepwise withdrawal of inhaled corticosteroids in COPD patients receiving dual bronchodilation: WISDOM study design and rationale
19. Pooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPD
20. Measuring habitual physical activity in adults with cystic fibrosis
21. Factor analysis in predominantly severe COPD: Identification of disease heterogeneity by easily measurable characteristics
22. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort
23. Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: A randomised trial
24. Physical activity monitoring in COPD: Compliance and associations with clinical characteristics in a multicenter study
25. Predicting Outcomes from 6-Minute Walk Distance in Chronic Obstructive Pulmonary Disease
26. Reported Pneumonia in Patients With COPD: Findings From the INSPIRE Study
27. Contributors
28. α;1-Antitrypsin Protease Inhibitor MZ Heterozygosity Is Associated With Airflow Obstruction in Two Large Cohorts
29. COPD Performance Measures: Missing Opportunities for Improving Care
30. COPD in the time of COVID-19
31. Prevalence and Progression of Osteoporosis in Patients With COPD: Results From the Towards a Revolution in COPD Health Study
32. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials
33. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials
34. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data
35. RISK OF DEATH AND COPD HOSPITALIZATION WITH FLUTICASONE FUROATE-CONTAINING THERAPY: POST HOC SUBGROUP ANALYSIS FROM THE SUMMIT TRIAL IN PATIENTS WITH COPD AND A HISTORY OF EXACERBATION
36. A Pooled Analysis of FEV1Decline in COPD Patients Randomized to Inhaled Corticosteroids or Placebo
37. What have we learned from large drug treatment trials in COPD?
38. BLOOD EOSINOPHILS AS A PREDICTIVE MARKER OF EXACERBATION RISK IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE: RESULTS FROM A POOLED ANALYSIS OF 22,125 PATIENTS
39. Palliative Treatment of Dyspnea With Epidural Methadone in Advanced Emphysema
40. Withdrawal From Treatment as an Outcome in the ISOLDE Study of COPD
41. 70 - Chronic Obstructive Pulmonary Disease
42. The Future for Tiotropium
43. COPD EXACERBATION RATE BY BASELINE COPD ASSESSMENT TEST SCORE IN THE DYNAGITO STUDY
44. TIOTROPIUM/OLODATEROL THERAPY IMPROVES LUNG FUNCTION, SYMPTOMS AND IMPACT OF DISEASE VS MONOTHERAPIES IN STEROID-FREE PATIENTS WITH COPD
45. Chapter 15 - Bronchodilators
46. HIGH-SENSITIVITY CARDIAC TROPONIN I AND RISK OF CARDIOVASCULAR EVENTS IN PATIENTS WITH COPD AND HEIGHTENED CARDIOVASCULAR RISK: A BIOMARKER SUB-STUDY OF THE SUMMIT TRIAL
47. PROGNOSTIC IMPORTANCE OF BLOOD PRESSURE AND HEART RATE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE: THE SUMMIT TRIAL
48. Contributors
49. COPD therapy: if two is good, is three better?
50. CARDIOVASCULAR OUTCOMES WITH AN INHALED LONG-ACTING BETA AGONIST AND CORTICOSTEROID IN PATIENTS WITH MODERATE CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND HEIGHTENED CARDIOVASCULAR RISK: THE SUMMIT TRIAL
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.